Cellectis SA (CLLS) Defies Sector Headwinds on Cancer Breakthrough

Cellectis SA (ADR) (CLLS) is flying high on an encouraging report on its leukemia treatment

May 6, 2016 at 2:32 PM
facebook X logo linkedin

Cellectis SA (ADR) (NASDAQ:CLLS) is defying healthcare-sector headwinds, after the biotech's "designer immune cells" have potentially cured a second baby of leukemia. At last check, the stock was up 14.7% at $30.91, and earlier hit a 2016 high of $31.17. While some on Wall Street were expecting big gains from CLLS, one group of bearish traders may be in trouble.

On the bullish side are analysts. All six of the brokerages covering CLLS have handed out a "strong buy" recommendation. Plus, the stock's average 12-month price target of $49.67 sits in territory not charted for nearly a year -- and at a lofty 61% premium to current trading levels.

By contrast, short sellers haven't been shy toward CLLS. While short interest dropped 23% during the last two reporting periods, a healthy 5% of the stock's float remains sold short. At the equity's typical trading levels, it would take more than eight sessions to buy back these shorted shares, indicating there's plenty of pent-up buying power that could help extend today's rally.

As alluded to previously, Cellectis SA (ADR) (NASDAQ:CLLS) is flirting with levels not seen since late 2015. However, the stock is currently just below its year-to-date breakeven mark of $31.03, which could act as resistance. As a matter of fact, this area repelled the shares in both March and April, when they topped out at $30.37 and $30.99, respectively.

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.


Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI